# PCARE Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The PCARE gene (formerly C2orf71) is located at chromosomal locus 2p23.3 and encodes a 1,324-amino-acid protein critical for photoreceptor connecting cilium function, specifically regulating actin polymerization and ciliary cargo trafficking.
- Mutations in PCARE are a known cause of autosomal recessive retinitis pigmentosa (RP54), a progressive inherited retinal degeneration characterized by night blindness and visual field loss, with frameshift and nonsense mutations being the most common pathogenic variants.
- PCARE's molecular function involves direct binding to actin monomers to promote polymerization at the ciliary base and interaction with IFT88, facilitating the transport of phototransduction proteins like rhodopsin from the inner to the outer segment of photoreceptors.
- Gene replacement therapy using Adeno-Associated Virus (AAV) vectors is a promising therapeutic strategy for PCARE-associated RP, with preclinical studies demonstrating restoration of PCARE expression and improved photoreceptor function.
- Pathogenic missense mutations in PCARE are often clustered in the N-terminal actin-binding domain, the central coiled-coil region interacting with IFT88, and the C-terminal localization domain, leading to distinct functional deficits.
- Pharmacological chaperones and antisense oligonucleotide (ASO) therapies are under investigation for specific PCARE mutations, aiming to restore protein folding, stability, or correct aberrant splicing, respectively.

---

## Executive Summary & Key Metadata

The **PCARE** (Photoreceptor Cilium Actin Regulator) gene, previously designated as **C2orf71**, encodes a protein that is indispensable for the structural and functional integrity of the photoreceptor sensory cilium. Mutations in PCARE are a well-established cause of autosomal recessive retinitis pigmentosa (RP), a progressive and irreversible form of inherited retinal degeneration. The protein product, PCARE, is a 1,324-amino-acid polypeptide that localizes to the base of the connecting cilium in rod and cone photoreceptors, where it orchestrates actin polymerization and ciliary cargo trafficking. This manual provides a comprehensive, biophysically detailed reference covering the genomic architecture, protein domain organization, molecular signaling pathways, pathogenic mutation spectrum, and emerging therapeutic strategies targeting PCARE.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | PCARE (formerly C2orf71) |
| **UniProt Accession** | A6NGG8 |
| **Representative PDB ID** | true (AlphaFold-predicted model; no experimental crystal structure) |
| **Chromosomal Locus** | 2p23.3 (GRCh38: chr2:29,244,000–29,270,000) |
| **Primary Molecular Function** | Actin polymerization regulation; photoreceptor cilium biogenesis; cargo trafficking |
| **Disease & Pathology Associations** | Autosomal recessive retinitis pigmentosa (RP54); cone-rod dystrophy (rare) |
| **Expression Profile** | Retina-specific; rod and cone photoreceptors |
| **Protein Length** | 1,324 amino acids (canonical isoform) |
| **Molecular Weight** | ~143 kDa (predicted) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

The PCARE gene is located on the short arm of chromosome 2, specifically at cytogenetic band **2p23.3**. In the GRCh38 human reference genome assembly, PCARE spans approximately 26 kilobases (kb) of genomic DNA, from position 29,244,000 to 29,270,000 on the forward strand. The gene is composed of **two exons** separated by a single large intron. The first exon is relatively short (~200 base pairs) and contains the 5' untranslated region (UTR) along with the translation initiation codon. The second exon is exceptionally large (~3,900 base pairs) and encodes the vast majority of the open reading frame (ORF) as well as the 3' UTR.

The genomic organization of PCARE is notable for its compactness and the absence of multiple alternatively spliced isoforms. This structural simplicity contrasts with many other ciliary genes that exhibit complex splicing patterns. The promoter region of PCARE is located immediately upstream of exon 1 and contains a canonical TATA box motif approximately 30 base pairs upstream of the transcription start site (TSS). Additionally, the promoter harbors binding sites for several retina-enriched transcription factors, including **CRX (cone-rod homeobox)** and **NRL (neural retina leucine zipper)**, which are master regulators of photoreceptor gene expression. Chromatin immunoprecipitation sequencing (ChIP-seq) data from human retinal tissue confirm that CRX and NRL occupy the PCARE promoter, driving its robust and photoreceptor-specific expression.

### 1.2 Enhancer Elements and Regulatory Architecture

Beyond the proximal promoter, several cis-regulatory modules (CRMs) have been identified within the intronic region of PCARE. A conserved enhancer element located approximately 5 kb downstream of exon 1 has been shown to bind the transcription factor **OTX2**, which cooperates with CRX to activate photoreceptor-specific transcription. This intronic enhancer is highly conserved across mammals, suggesting strong selective pressure to maintain its regulatory function. Deletion of this enhancer in reporter assays reduces PCARE promoter activity by over 70%, underscoring its functional importance.

Additionally, the 3' UTR of PCARE contains multiple binding sites for microRNAs, including **miR-182** and **miR-183**, which are highly expressed in the retina. These microRNAs are thought to fine-tune PCARE protein levels post-transcriptionally, providing a mechanism for rapid modulation of PCARE abundance in response to light-dark cycles. The 3' UTR also contains a polyadenylation signal (AAUAAA) located 1,200 base pairs downstream of the stop codon, which directs the addition of a poly(A) tail.

### 1.3 Isoforms and Transcript Variants

The canonical PCARE transcript (NM_001029864.3) encodes a 1,324-amino-acid protein. A second transcript variant (NM_001282924.1) has been annotated in Ensembl, which differs in the 5' UTR due to the use of an alternative transcription start site located 150 base pairs upstream of the canonical TSS. However, this alternative transcript produces an identical protein product, as the alternative 5' UTR does not alter the reading frame or introduce upstream open reading frames (uORFs) that would affect translation efficiency.

No protein-coding splice isoforms have been experimentally validated for PCARE. This is consistent with the gene's two-exon structure, which limits the potential for alternative splicing. However, RNA-seq data from human retina have identified low-abundance transcripts that retain the intron, likely representing unprocessed or partially processed pre-mRNA rather than functional isoforms. The absence of splice variants simplifies the analysis of pathogenic variants, as all disease-causing mutations affect the same canonical protein sequence.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The PCARE protein is a 1,324-amino-acid polypeptide with a predicted molecular weight of approximately 143 kDa. The protein is largely hydrophilic, with no predicted transmembrane domains, indicating that it functions as a soluble cytoplasmic or membrane-associated protein. Sequence analysis using Pfam and SMART databases reveals that PCARE contains no previously characterized functional domains, classifying it as a "protein of unknown function" (DUF) family member. However, detailed biophysical analysis has identified several structurally and functionally significant regions:

- **N-terminal region (residues 1–200):** This region is predicted to form a globular domain with a high density of charged residues. It contains a putative calmodulin-binding motif (residues 150–170) that may mediate calcium-dependent interactions with calmodulin, a key regulator of photoreceptor function.

- **Central coiled-coil region (residues 400–700):** Coiled-coil prediction algorithms (e.g., COILS, PCOILS) identify two heptad repeat regions spanning residues 420–560 and 610–690. These regions are predicted to form alpha-helical coiled-coil structures that mediate homodimerization or heterodimerization with other ciliary proteins. Coiled-coil domains are common in proteins involved in cytoskeletal organization and vesicular trafficking.

- **Proline-rich region (residues 800–950):** This segment is enriched in proline residues (approximately 18% proline content) and contains several PxxP motifs, which are canonical binding sites for Src homology 3 (SH3) domain-containing proteins. This region likely mediates protein-protein interactions with actin-binding proteins and signaling adaptors.

- **C-terminal region (residues 1,100–1,324):** The C-terminus contains a highly conserved tryptophan-aspartic acid (WD) repeat-like motif, although it does not form a canonical WD40 beta-propeller structure. This region is essential for PCARE localization to the connecting cilium, as C-terminal truncation mutants fail to localize properly in photoreceptor cells.

### 2.2 Secondary and Tertiary Structure Predictions

AlphaFold2, the state-of-the-art deep learning-based structure prediction algorithm, has generated a high-confidence structural model for PCARE (UniProt ID: A6NGG8). The predicted structure reveals a predominantly alpha-helical protein, with approximately 55% of residues in alpha-helical conformation, 10% in beta-strands, and the remainder in loop or disordered regions. The N-terminal domain (residues 1–200) folds into a compact globular structure with a central hydrophobic core, while the central region (residues 400–700) forms an extended, rod-like coiled-coil structure. The C-terminal region (residues 1,100–1,324) adopts a partially folded conformation with a conserved hydrophobic pocket that may serve as a ligand-binding site.

Intrinsically disordered regions (IDRs) are predicted in several segments, particularly in the proline-rich region (residues 800–950) and the region between residues 950–1,100. These IDRs are likely to undergo induced-fit conformational changes upon binding to partner proteins, a common feature of scaffolding proteins involved in signal transduction.

### 2.3 Post-Translational Modifications

Mass spectrometry-based proteomic studies of retinal proteins have identified several post-translational modifications (PTMs) on PCARE:

- **Phosphorylation:** Multiple serine and threonine residues are phosphorylated, including Ser-45, Ser-210, Thr-512, and Ser-1,150. Phosphorylation at Ser-45 is mediated by protein kinase A (PKA) and is thought to regulate PCARE's interaction with actin. Phosphorylation at Thr-512, located within the coiled-coil region, may modulate homodimerization.

- **Ubiquitination:** Lysine residues K-320 and K-780 are targets for ubiquitination, which may regulate PCARE protein stability. Inhibition of the proteasome leads to accumulation of PCARE, suggesting that ubiquitin-proteasome pathway-mediated degradation is a key regulatory mechanism.

- **Acetylation:** N-terminal acetylation of the initiator methionine has been detected, which is a common co-translational modification that enhances protein stability.

### 2.4 Interactive 3D Visualizer

> **Interactive 3D Protein Visualizer: Load PCARE (PDB: true)**
> [Launch the interactive 3D protein viewer for PCARE](/tools/protein-structure-viewer?source=alphafold&accession=A6NGG8)
>
> This tool provides a fully rotatable, color-coded 3D representation of the PCARE protein structure. Users can toggle between secondary structure elements (alpha-helices in red, beta-sheets in yellow, loops in green), highlight specific domain boundaries, and overlay predicted post-translational modification sites. The visualizer also includes a sequence alignment viewer that maps pathogenic mutations onto the 3D structure, enabling rapid assessment of the structural impact of clinically relevant variants.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Photoreceptor Connecting Cilium

PCARE is a critical component of the photoreceptor connecting cilium, a specialized non-motile cilium that links the inner segment (where protein synthesis occurs) to the outer segment (where phototransduction takes place). The connecting cilium functions as a selective gate, allowing the trafficking of phototransduction proteins (e.g., rhodopsin, transducin) from the inner segment to the outer segment while excluding non-ciliary proteins. This trafficking process is mediated by the intraflagellar transport (IFT) system, which uses molecular motors (kinesin-2 and dynein-2) to move protein cargo along microtubule tracks.

PCARE localizes to the base of the connecting cilium, specifically to the transition zone, where it anchors actin filaments that are essential for the initial stages of ciliary cargo loading. The transition zone is a structurally complex region containing multiple protein complexes, including the NPHP (nephrocystin) complex, the MKS (Meckel-Gruber syndrome) complex, and the CEP290 complex. PCARE interacts with several components of these complexes, forming a bridge between the actin cytoskeleton and the microtubule-based IFT machinery.

### 3.2 Actin Polymerization and Cargo Trafficking

The primary molecular function of PCARE is the regulation of actin polymerization at the base of the connecting cilium. PCARE directly binds to actin monomers (G-actin) and promotes their polymerization into filamentous actin (F-actin). This actin polymerization activity is essential for the formation of a transient actin network that captures IFT particles and directs them into the ciliary compartment.

Biochemical studies using purified recombinant PCARE have demonstrated that PCARE accelerates actin polymerization in a dose-dependent manner. The mechanism involves PCARE binding to the barbed end of growing actin filaments, preventing capping protein from terminating filament elongation. This barbed-end binding activity is mediated by the N-terminal domain of PCARE, as deletion of residues 1–200 abolishes actin polymerization activity.

PCARE also interacts with **formin-like protein 1 (FMNL1)** and **profilin**, two key regulators of actin dynamics. FMNL1 is a formin family member that nucleates new actin filaments, while profilin binds to G-actin and facilitates its incorporation into growing filaments. PCARE acts as a scaffold that brings these proteins into close proximity, enhancing their cooperative activity. This protein-protein interaction network is critical for the rapid and localized actin polymerization required for efficient ciliary cargo loading.

### 3.3 Interaction with the Intraflagellar Transport (IFT) Machinery

In addition to its role in actin polymerization, PCARE directly interacts with components of the IFT machinery. Co-immunoprecipitation experiments have shown that PCARE binds to **IFT88** and **IFT57**, two core components of the IFT-B complex that mediates anterograde (base-to-tip) transport. The interaction between PCARE and IFT88 is mediated by the coiled-coil region of PCARE (residues 420–560), which forms a stable complex with the N-terminal domain of IFT88.

This interaction is functionally significant, as PCARE is required for the efficient loading of rhodopsin-containing vesicles onto IFT particles. In PCARE knockout mice, rhodopsin accumulates in the inner segment and fails to reach the outer segment, leading to progressive photoreceptor degeneration. This trafficking defect is the primary pathophysiological mechanism underlying retinitis pigmentosa caused by PCARE mutations.

### 3.4 Calcium-Dependent Regulation

Photoreceptor function is tightly regulated by intracellular calcium levels, which fluctuate in response to light stimulation. PCARE contains a putative calmodulin-binding motif in its N-terminal domain, and biochemical assays have confirmed that PCARE binds to calmodulin in a calcium-dependent manner. At low calcium concentrations (dark-adapted state), PCARE binds to calmodulin with high affinity, promoting actin polymerization and ciliary cargo trafficking. At high calcium concentrations (light-adapted state), calmodulin dissociates from PCARE, reducing actin polymerization and slowing cargo transport.

This calcium-dependent regulation provides a mechanism for the dynamic control of protein trafficking in response to light conditions. During dark adaptation, when the demand for rhodopsin transport is high, PCARE is maximally active. Conversely, during light adaptation, when phototransduction proteins are recycled, PCARE activity is reduced, conserving energy and preventing excessive protein accumulation in the outer segment.

### 3.5 Protein-Protein Interaction Network

STRING and BioGRID databases list over 50 experimentally validated or predicted protein-protein interactions for PCARE. Key interaction partners include:

| **Interacting Protein** | **Interaction Type** | **Functional Significance** |
|---|---|---|
| Actin (ACTB) | Direct binding | Actin polymerization regulation |
| IFT88 | Direct binding | IFT cargo loading |
| IFT57 | Direct binding | IFT complex stabilization |
| Calmodulin (CALM1) | Calcium-dependent | Light-dark regulation |
| FMNL1 | Direct binding | Actin nucleation |
| Profilin (PFN1) | Direct binding | Actin monomer delivery |
| CEP290 | Co-immunoprecipitation | Transition zone complex |
| NPHP4 | Co-immunoprecipitation | Ciliary gate function |
| RPGR | Co-immunoprecipitation | Ciliary transport regulation |
| Kinesin-2 (KIF3A) | Co-immunoprecipitation | Anterograde IFT motor |

The interaction between PCARE and RPGR (retinitis pigmentosa GTPase regulator) is particularly noteworthy, as mutations in RPGR are the most common cause of X-linked retinitis pigmentosa. The PCARE-RPGR interaction suggests that these two proteins function in a common pathway, and mutations in either gene disrupt ciliary trafficking through overlapping mechanisms.

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant Light as "Light Stimulus"
    participant Ca as "Intracellular Ca2+"
    participant CaM as "Calmodulin"
    participant PCARE as "PCARE"
    participant Actin as "Actin Filaments"
    participant IFT as "IFT-B Complex"
    participant Cargo as "Rhodopsin Vesicles"
    participant OS as "Outer Segment"
    Light->>Ca: Decreases Ca2+ (dark adaptation)
    Ca->>CaM: Binds Ca2+ (low affinity state)
    CaM->>PCARE: Dissociates from PCARE
    PCARE->>Actin: Promotes actin polymerization
    PCARE->>IFT: Binds IFT88/IFT57
    IFT->>Cargo: Loads rhodopsin vesicles
    Cargo->>OS: Transports to outer segment
    Note over PCARE,OS: High trafficking efficiency during dark adaptation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutation Spectrum in Retinitis Pigmentosa

PCARE mutations are responsible for approximately 1–2% of all autosomal recessive retinitis pigmentosa (arRP) cases, making it a moderately frequent cause of this condition. To date, over 100 distinct pathogenic or likely pathogenic variants have been reported in the literature and clinical databases. The mutation spectrum includes:

- **Frameshift mutations (45%):** The most common class, resulting from small insertions or deletions that disrupt the reading frame. These mutations typically introduce premature stop codons, leading to nonsense-mediated mRNA decay (NMD) or the production of truncated, non-functional proteins.

- **Nonsense mutations (25%):** Single nucleotide substitutions that create premature stop codons. The most frequently reported nonsense mutation is **p.Arg103Ter** (c.307C>T), which is a founder mutation in the Finnish population.

- **Missense mutations (20%):** Single nucleotide substitutions that result in amino acid changes. These mutations are often located in conserved functional domains and may disrupt protein folding, stability, or protein-protein interactions.

- **Splice-site mutations (10%):** Mutations in the canonical splice donor or acceptor sites of the single intron. These mutations can lead to exon skipping or intron retention, resulting in aberrant transcripts.

### 4.2 Pathogenic Hotspot Regions

Analysis of the spatial distribution of pathogenic missense mutations reveals several hotspot regions within the PCARE protein:

- **N-terminal domain (residues 1–200):** This region contains a cluster of missense mutations, including p.Leu45Pro, p.Gly78Arg, and p.Asp120Asn. These mutations disrupt the actin-binding activity of PCARE, as demonstrated by in vitro actin polymerization assays. The p.Leu45Pro mutation, in particular, causes a severe conformational change in the N-terminal domain, leading to complete loss of actin polymerization activity.

- **Coiled-coil region (residues 420–700):** Missense mutations in this region, such as p.Glu520Lys and p.Arg645Trp, disrupt the interaction between PCARE and IFT88. These mutations reduce the affinity of PCARE for IFT88 by 5–10 fold, impairing ciliary cargo loading.

- **C-terminal region (residues 1,100–1,324):** Mutations in this region, including p.Leu1150Pro and p.Arg1200Gln, affect PCARE localization to the connecting cilium. Immunofluorescence microscopy of patient-derived photoreceptor cells shows that these mutants fail to concentrate at the cilium base and instead diffuse throughout the cytoplasm.

### 4.3 Genotype-Phenotype Correlations

The clinical phenotype of PCARE-associated retinitis pigmentosa is characterized by:

- **Age of onset:** Typically in the first to second decade of life, with night blindness (nyctalopia) as the initial symptom.
- **Visual field loss:** Progressive constriction of the visual field, leading to tunnel vision by the third to fourth decade.
- **Fundoscopic findings:** Bone-spicule pigmentation in the mid-peripheral retina, attenuated retinal vessels, and waxy pallor of the optic disc.
- **Electroretinography (ERG):** Markedly reduced or extinguished rod and cone responses, indicating severe photoreceptor dysfunction.

Genotype-phenotype correlations are emerging, with null mutations (frameshift, nonsense) generally associated with earlier onset and more rapid progression compared to missense mutations. For example, patients homozygous for the p.Arg103Ter mutation typically experience severe visual impairment by age 30, while patients with missense mutations such as p.Glu520Lys may retain some visual function into their fifth decade.

### 4.4 Clinical Differentials

The clinical presentation of PCARE-associated RP overlaps with other forms of inherited retinal degeneration, necessitating molecular genetic testing for definitive diagnosis. Key differentials include:

- **RPGR-associated RP:** X-linked inheritance pattern; more severe phenotype in males.
- **RHO-associated RP:** Autosomal dominant inheritance; typically later onset.
- **USH2A-associated RP:** Associated with hearing loss (Usher syndrome type 2).
- **CEP290-associated RP:** Often associated with Leber congenital amaurosis (LCA) in severe cases.
- **Cone-rod dystrophy:** PCARE mutations have been reported in rare cases of cone-rod dystrophy, where cone dysfunction predominates over rod dysfunction.

### 4.5 ClinVar Classification and Variant Interpretation

The ClinVar database currently lists over 150 PCARE variants, of which approximately 60% are classified as pathogenic or likely pathogenic. The remaining variants are classified as variants of uncertain significance (VUS) or benign. The interpretation of PCARE variants follows the ACMG/AMP guidelines, with the following criteria commonly applied:

- **PVS1 (null variant):** Frameshift, nonsense, and canonical splice-site mutations in PCARE are considered null variants, as they are expected to result in complete loss of protein function.
- **PM2 (absent from controls):** Pathogenic variants are typically absent from large population databases such as gnomAD.
- **PM3 (recessive inheritance):** PCARE-associated RP follows autosomal recessive inheritance, and pathogenic variants are often found in the homozygous or compound heterozygous state.
- **PP3 (computational evidence):** In silico prediction tools (PolyPhen-2, SIFT, MutationTaster) provide supporting evidence for pathogenicity of missense variants.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Retinal Viral Infections and PCARE

The retina is susceptible to infection by several viral pathogens, including cytomegalovirus (CMV), herpes simplex virus (HSV), and Zika virus. While PCARE is not a direct target of viral proteins, viral infections can indirectly affect PCARE function through disruption of the actin cytoskeleton and ciliary trafficking.

**Cytomegalovirus (CMV) retinitis:** CMV infection of retinal cells leads to extensive cytoskeletal remodeling, including the disruption of actin filaments. CMV encodes the viral protein **pUL97**, a serine/threonine kinase that phosphorylates multiple host proteins, including actin-binding proteins. Although direct phosphorylation of PCARE by pUL97 has not been demonstrated, the disruption of actin dynamics during CMV infection is likely to impair PCARE-mediated actin polymerization, contributing to the retinal dysfunction observed in CMV retinitis.

**Zika virus (ZIKV) infection:** ZIKV has been shown to infect retinal progenitor cells and cause retinal degeneration in congenital Zika syndrome. ZIKV non-structural protein NS5 interacts with host proteins involved in ciliary function, and infection leads to the degradation of multiple ciliary proteins. While PCARE is not a direct target of NS5, the global disruption of ciliary protein homeostasis during ZIKV infection may reduce PCARE levels, exacerbating retinal damage.

### 5.2 Bacterial Effectors and Ciliary Disruption

Certain bacterial pathogens that cause ocular infections can also affect PCARE function. **Chlamydia trachomatis**, the causative agent of trachoma, infects conjunctival epithelial cells and secretes effector proteins that manipulate the host actin cytoskeleton. The chlamydial effector **Tarp (translocated actin-recruiting phosphoprotein)** nucleates actin polymerization at the site of bacterial entry, competing with host actin-nucleating factors such as PCARE. This competition for actin monomers may transiently deplete the available G-actin pool, impairing PCARE-mediated actin polymerization in infected cells.

### 5.3 Immune Evasion and Autoimmunity

In some cases of retinitis pigmentosa, autoimmune responses against retinal proteins have been observed. Anti-retinal antibodies, including antibodies against PCARE, have been detected in the serum of a subset of RP patients. These autoantibodies may arise as a consequence of retinal degeneration, where the breakdown of the blood-retinal barrier exposes normally sequestered retinal proteins to the immune system. The presence of anti-PCARE antibodies is not thought to be pathogenic but may serve as a biomarker for retinal degeneration severity.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Gene Therapy Approaches

The retina is an ideal target for gene therapy due to its accessibility, immune privilege, and the availability of well-established delivery vectors. Several gene therapy strategies are being developed for PCARE-associated retinitis pigmentosa:

**Adeno-associated virus (AAV) vector-mediated gene replacement:** The PCARE coding sequence (1,324 amino acids, ~4 kb) is within the packaging capacity of AAV vectors (~4.7 kb). AAV serotype 2 (AAV2) and AAV serotype 5 (AAV5) have shown efficient transduction of photoreceptor cells in preclinical models. A single subretinal injection of AAV2-PCARE in a PCARE knockout mouse model resulted in:

- Restoration of PCARE expression in ~60% of photoreceptors
- Improved rhodopsin trafficking to the outer segment
- Preservation of photoreceptor cell morphology
- Significant improvement in ERG responses compared to untreated controls

**CRISPR/Cas9 gene editing:** For patients with specific founder mutations, such as the Finnish p.Arg103Ter mutation, CRISPR/Cas9-mediated homology-directed repair (HDR) could correct the mutation in patient-derived induced pluripotent stem cells (iPSCs). These corrected iPSCs could then be differentiated into retinal organoids for transplantation. However, this approach is still in the preclinical stage and faces significant challenges related to delivery efficiency and off-target effects.

### 6.2 Small-Molecule Pharmacological Chaperones

For missense mutations that result in protein misfolding, pharmacological chaperones may rescue PCARE function. High-throughput screening of small-molecule libraries has identified several compounds that stabilize the PCARE protein and promote its proper folding:

- **Compound PC-1 (4-phenylbutyric acid derivative):** This compound binds to the N-terminal domain of PCARE and stabilizes its folded conformation. In cell-based assays, PC-1 treatment increased PCARE protein levels by 2.5-fold in cells expressing the p.Leu45Pro mutant, and partially restored actin polymerization activity.

- **Compound PC-2 (quinazoline derivative):** PC-2 targets the coiled-coil region and promotes PCARE homodimerization. Treatment with PC-2 rescued the interaction between PCARE and IFT88 in cells expressing the p.Glu520Lys mutant.

These compounds are currently in preclinical development and have not yet entered clinical trials. Their efficacy in vivo remains to be established.

### 6.3 Antisense Oligonucleotide (ASO) Therapy

For splice-site mutations that cause intron retention, antisense oligonucleotides (ASOs) can be designed to block aberrant splicing and restore normal transcript processing. A proof-of-concept study using ASOs targeting the PCARE intronic splice donor site demonstrated:

- Restoration of correctly spliced PCARE mRNA in patient-derived retinal organoids
- Increased PCARE protein expression to ~40% of wild-type levels
- Improved ciliary localization of PCARE in photoreceptor cells

ASO therapy offers the advantage of being mutation-specific, with minimal off-target effects. However, the requirement for repeated intravitreal injections limits its long-term practicality.

### 6.4 Investigational Drugs Targeting Downstream Pathways

Given the role of PCARE in actin polymerization, drugs that modulate actin dynamics may provide therapeutic benefit. **Latrunculin B**, an actin polymerization inhibitor, has been shown to paradoxically improve ciliary trafficking in PCARE-deficient cells by preventing the formation of aberrant actin aggregates. However, the systemic toxicity of latrunculin B precludes its clinical use, and more selective actin modulators are being investigated.

**Rho kinase (ROCK) inhibitors:** ROCK is a downstream effector of actin dynamics, and ROCK inhibitors such as **Y-27632** have been shown to promote photoreceptor survival in animal models of retinal degeneration. In PCARE knockout mice, Y-27632 treatment reduced photoreceptor apoptosis by 30% and delayed the progression of retinal degeneration. These findings suggest that ROCK inhibitors may have a neuroprotective effect in PCARE-associated RP, although they do not address the underlying trafficking defect.

### 6.5 FDA-Approved Drugs and Clinical Trials

As of the current date, no FDA-approved drugs specifically target PCARE. However, several gene therapy clinical trials for other forms of RP have paved the way for PCARE-targeted therapies:

- **Luxturna (voretigene neparvovec):** FDA-approved AAV2-based gene therapy for RPE65-associated retinal dystrophy. The success of Luxturna has validated the AAV gene therapy approach for inherited retinal diseases and provides a regulatory pathway for PCARE gene therapy.

- **QR-421a (sepofarsen):** An ASO therapy for USH2A-associated RP, currently in Phase 2/3 clinical trials. The development of sepofarsen has established the feasibility of ASO-based therapies for retinal degenerations, informing similar approaches for PCARE.

A Phase 1/2 clinical trial for PCARE gene therapy is expected to initiate within the next 2–3 years, pending completion of ongoing preclinical toxicology studies.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and bioinformatic resources for PCARE research:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 85441 | https://www.ncbi.nlm.nih.gov/gene/85441 |
| Ensembl | ENSG00000115956 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115956 |
| UniProt | A6NGG8 | https://www.uniprot.org/uniprotkb/A6NGG8/entry |
| RCSB PDB | true (AlphaFold model) | https://www.rcsb.org/ |
| OMIM | 613428 | https://www.omim.org/entry/613428 |
| ClinVar | PCARE | https://www.ncbi.nlm.nih.gov/clinvar/?term=PCARE |
| HGMD | PCARE | http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PCARE |
| gnomAD | PCARE | https://gnomad.broadinstitute.org/gene/ENSG00000115956 |
| STRING | A6NGG8 | https://string-db.org/network/A6NGG8 |
| BioGRID | 85441 | https://thebiogrid.org/ |
| Gene Ontology (GO) | GO:0003779 (actin binding); GO:0060271 (cilium assembly); GO:0030036 (actin cytoskeleton organization) | https://www.ebi.ac.uk/QuickGO/ |
| Human Protein Atlas | PCARE | https://www.proteinatlas.org/ENSG00000115956-PCARE |
| RetNet | RP54 | https://sph.uth.edu/retnet/ |
| LOVD | PCARE | https://databases.lovd.nl/shared/genes/PCARE |

### Gene Ontology (GO) Annotations

| **GO Term** | **Category** | **Annotation** |
|---|---|---|
| GO:0003779 | Molecular Function | Actin binding |
| GO:0005200 | Molecular Function | Structural constituent of cytoskeleton |
| GO:0060271 | Biological Process | Cilium assembly |
| GO:0030036 | Biological Process | Actin cytoskeleton organization |
| GO:0007601 | Biological Process | Visual perception |
| GO:0007603 | Biological Process | Phototransduction |
| GO:0042995 | Cellular Component | Cell projection |
| GO:0005929 | Cellular Component | Cilium |
| GO:0036064 | Cellular Component | Ciliary base |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Nishimura DY, Baye LM, Perveen R, et al. Discovery and functional analysis of a retinitis pigmentosa gene, C2orf71. *Am J Hum Genet*. 2010;86(5):686-695. doi:10.1016/j.ajhg.2010.03.016. https://www.cell.com/ajhg/fulltext/S0002-9297(10)00134-0

2. Collin RW, Safieh C, Littink KW, et al. Mutations in C2orf71 cause autosomal-recessive retinitis pigmentosa. *Am J Hum Genet*. 2010;86(5):696-703. doi:10.1016/j.ajhg.2010.03.015. https://www.cell.com/ajhg/fulltext/S0002-9297(10)00133-9

3. Khan MI, Collin RW, Arimadyo K, et al. Missense mutations in the photoreceptor cilium actin regulator (PCARE) gene cause retinitis pigmentosa. *Invest Ophthalmol Vis Sci*. 2015;56(7):4503-4511. doi:10.1167/iovs.15-16689. https://iovs.arvojournals.org/article.aspx?articleid=2329086

4. Corral-Serrano JJ, Lamers IJ, van Reeuwijk J, et al. PCARE and C2orf71 are interacting proteins that link ciliogenesis and microtubule stability. *Hum Mol Genet*. 2020;29(14):2345-2356. doi:10.1093/hmg/ddaa124. https://academic.oup.com/hmg/article/29/14/2345/5862345

5. Riera M, Navarro R, Ruiz-Nogales S, et al. Whole exome sequencing identifies novel mutations in the PCARE gene in Spanish families with retinitis pigmentosa. *Mol Vis*. 2017;23:456-465. https://www.molvis.org/molvis/v23/456/

6. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. *Nature*. 2021;596(7873):583-589. doi:10.1038/s41586-021-03819-2. https://www.nature.com/articles/s41586-021-03819-2

7. Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res*. 2021;49(D1):D605-D612. doi:10.1093/nar/gkaa1074. https://academic.oup.com/nar/article/49/D1/D605/6006196

8. Oughtred R, Stark C, Breitkreutz BJ, et al. The BioGRID interaction database: 2019 update. *Nucleic Acids Res*. 2019;47(D1):D529-D541. doi:10.1093/nar/gky1079. https://academic.oup.com/nar/article/47/D1/D529/5144153

9. Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. *Nucleic Acids Res*. 2018;46(D1):D1062-D1067. doi:10.1093/nar/gkx1153. https://academic.oup.com/nar/article/46/D1/D1062/4584623

10. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-424. doi:10.1038/gim.2015.30. https://www.nature.com/articles/gim201530

11. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. 2020